Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The latest announcement is out from ConvaTec ( (GB:CTEC) ).
ConvaTec reported first-half 2026 revenue of $1,232 million, up 4.4% year-on-year, with organic growth of 5.0% excluding InnovaMatrix and adjusted operating profit rising 3.9% to $262 million, despite a $69 million non-cash impairment tied to reimbursement changes for InnovaMatrix in the U.S. Adjusted diluted EPS increased 6.3%, the interim dividend was lifted 15%, and the group announced a $200 million share buyback to be completed by year-end.
Growth was broad-based across all chronic care categories, led by strong new product launches such as ConvaFoam, Esteem Body and GentleCath Air, and robust infusion care demand, particularly for diabetes and Parkinson’s therapies. Management reaffirmed 2026 guidance for mid-single-digit organic revenue growth, margin expansion to at least 23%, double-digit EPS growth and around 100% equity cash conversion, and reiterated medium-term Accelerate strategy targets for operating margins in the mid‑20s and sustainable 6–8% annual revenue growth from 2027, underlining confidence in long-term execution despite InnovaMatrix-related headwinds.
The most recent analyst rating on (GB:CTEC) stock is a Buy
with a £315.00 price target.
To see the full list of analyst forecasts on ConvaTec stock,
see the GB:CTEC Stock Forecast page.
Spark’s Take on CTEC Stock
According to Spark, TipRanks’ AI Analyst, CTEC is a Neutral.
The score is driven primarily by solid underlying financial performance (growth, improving operating margins, positive free cash flow) and supportive guidance for continued growth and margin expansion. This is tempered by increased leverage and notable operational/regulatory risks flagged on the call, while valuation looks expensive and technicals appear near overbought despite an uptrend.
To see Spark’s full report on CTEC stock,
click here.
More about ConvaTec
ConvaTec Group PLC is a global medical products and technologies company focused on chronic care, operating across advanced wound care, ostomy care, continence care and infusion care. The business targets hospital and home-care settings, supplying solutions for conditions such as diabetes, Parkinson’s disease and long‑term catheter use, with a growing emphasis on product innovation and international expansion.
Average Trading Volume: 8,267,108
Technical Sentiment Signal: Buy
Current Market Cap: £4.37B
See more data about CTEC stock on TipRanks’ Stock Analysis page.